By Emily Field ( March 15, 2017, 7:11 PM EDT) -- A U.S. Food and Drug Administration advisory committee tasked with reviewing the risks of Endo Pharmaceutical's opioid painkiller Opana ER determined that they outweigh its benefits on Tuesday, following a two-day discussion of whether the pills' reformulation deterred abuse....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.